Table 4.
Recent updates of CAR‐T cell therapy for multiple myeloma at the 2021 ASH annual meeting
| Clinical trials (reference) | MCARH109 [68] |
Ide‐Cel (KarMMA) [67] | Cilta‐Cel (CARTITUDE‐1) [69, 112] |
Cilta‐Cel (CARTITUDE‐2) [73] |
CT053 (Lummicar and CG study) [70] | CT103A [76, 77] | bb21217 (CRB‐402) [75] |
|---|---|---|---|---|---|---|---|
| Phase | 1 | 2 | 1b/2 |
2 Cohort B |
1 | 1/2 | 1 |
| Patients (n) | 12 | 128 | 97 | 18 | 38 | 71 | 72 |
| Target | GPRC5D | BCMA | 2‐epitope BCMA | 2‐epitope BCMA | BCMA | BCMA | BCMA with PI3Ki bb007 |
| Medium number of previous lines of therapy | 8 | 6 | 6 | 1 (early relapse after initial therapy) | ≥ 2 | 4 | 6 |
| Prior ASCT | NA | 94% | NA | 77.8% | NA | 28.2% (18.3% with previous CAR-T therapy) | NA |
|
Response rate (ORR/CR) |
ORR 83% |
ORR 73% CR 33% |
ORR 97.9% CR 80.4% |
ORR 88.9% CR 27.8% |
ORR 92.1% CR 78.9% |
ORR 96% CR 54% |
ORR 69% CR 28% |
| OS | NA | Median 19.4 months | 18-month 80.9% | NA | NA | NA | NA |
| PFS | 13-week 75% | Median 8.8 months | 18-month 66% | NA | Median 22.7 months | NA | NA |
| CRS, any grade | 92% | 84% | 94.8% | 83.3% | 73.7% | 93% | 75% |
| ICANS, any grade | 0 | 18% | 21% | 5.6% | 0 | 1.4% | 15% |
| Grade ≥ 3 neutropenia | NA | 89% | 94.8% | NA | NA | NA | NA |
| Grade ≥ 3 thrombocytopenia | NA | 52% | 59.8% | NA | NA | NA | NA |
| Follow-up (months) | 3.0 | 13.3 | 18 | 4.7 | 13.9 | 4.9 | 9 |
NA not applicable